Spots Global Cancer Trial Database for A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
Official Title: A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
Study ID: NCT06138483
Conditions
Interventions
Study Description
Brief Summary: Inclusion of new biomarkers to improve the personalized treatment approach for HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC) patients is urgently needed. Emerging evidences suggest that mutations in epigenetic regulators, as well as epigenetic changes, deeply influence the biology of OPSCC, thus representing attractive targets for the definition of novel molecular markers for this malignancy. Based on these considerations, our project aims to retrospectively identify a new mutational and epigenetic signature to identify OPSCC patients at high risk of early relapse, and to set up a new multicenter prospective study in order to validate it
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, , Italy
Ospedale San Martino di Belluno - ULSS 1 Dolomiti, Belluno, , Italy
Ospedale dell'Angelo - Mestre - Ulss 3 Serenissima, Mestre, , Italy
Ospedale Santa Maria degli Angeli - ASFO, Pordenone, , Italy
Ospedale di Treviso - ULSS 2 Marca Trevigiana, Treviso, , Italy
Contact Details
Name: Elisabetta Fratta, PhD
Affiliation: Centro di Riferimento Oncologico (CRO), IRCCS
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
